Xenon Pharmaceuticals (Nasdaq: XENE) announced inducement equity grants to seven new non-officer employees comprising an aggregate of 25,600 share options and 15,000 restricted share units (RSUs), effective April 30, 2026, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
The share options carry a $56.04 exercise price, vest over four years, have a 10-year term, and RSUs vest 25% annually over four years, all subject to the company’s inducement equity incentive plan and continued service requirements.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
None.
Negative
None.
News Market Reaction – XENE
+2.26%
1 alert
+2.26%News Effect
On the day this news was published, XENE gained 2.26%, reflecting a moderate positive market reaction.
Share options granted:25,600 optionsRSUs granted:15,000 RSUsOption exercise price:$56.04 per share+5 more
8 metrics
Share options granted25,600 optionsInducement grants to seven new non-officer employees
RSUs granted15,000 RSUsInducement grants under Nasdaq Listing Rule 5635(c)(4)
Option exercise price$56.04 per shareEqual to XENE closing price on April 30, 2026
Option term10 yearsTerm of inducement share option grants
Option vesting4 years25% after one year, then monthly vesting thereafter
RSU vesting4 years25% on each of first four anniversaries of start date
Azetukalner stagePhase 3 trialsPrograms in epilepsy, MDD and bipolar depression
Early-stage programsKV7 and NaV1.7Pain-focused potassium and sodium channel modulators in Phase 1
Market Reality Check
Price:$51.73Vol:Volume 1,337,439 is 1.5x ...
normal vol
$51.73Last Close
VolumeVolume 1,337,439 is 1.5x the 20-day average of 890,510, indicating elevated trading activity ahead of this filing.normal
TechnicalShares at $56.04 are above the 200-day MA of $43.14 and about 12.37% below the $63.95 52-week high, near the upper end of the $28.19–$63.95 range.
Peers on Argus
XENE was modestly higher while key biotech peers like VKTX (+2.3%), RARE (+0.69%...
XENE was modestly higher while key biotech peers like VKTX (+2.3%), RARE (+0.69%), IMVT (+0.5%), and SRRK (+0.34%) also traded up, with SLNO roughly flat (-0.01%). No peers appeared in the momentum scanner, suggesting this inducement-grant news was company-specific rather than part of a strong sector rotation.
Priced upsized $650.0M public offering of common shares and pre-funded warrants.
Pattern Detected
Positive clinical and financing news has sometimes been met with selling pressure, particularly around large offerings, while one recent clinical preview saw a modestly positive reaction.
Recent Company History
Over the last few months, Xenon has reported several major milestones. In March 2026, it priced and closed an upsized public offering totaling roughly $650.0M–$747.5M in gross proceeds, which saw shares trade down 2.59–4.61% on the subsequent days. In April 2026, it highlighted and then presented Phase 3 azetukalner X-TOLE2 data and long-term seizure outcomes at the AAN meeting; despite strong efficacy figures, the main data release saw a -4.37% reaction. Today’s Nasdaq Rule 5635(c)(4) inducement grants fit into this ongoing equity and talent expansion story.
Market Pulse Summary
This announcement outlines routine inducement equity grants—25,600 options and 15,000 RSUs at an exe...
Analysis
This announcement outlines routine inducement equity grants—25,600 options and 15,000 RSUs at an exercise price of $56.04—under Nasdaq Listing Rule 5635(c)(4), tied to the Amended and Restated 2025 Inducement Equity Incentive Plan. The company has recently expanded this plan via an 8-K and raised substantial capital through offerings in March 2026. With azetukalner in Phase 3 and additional KV7/NaV1.7 programs in Phase 1, investors may watch future disclosures on total equity overhang, clinical milestones, and governance actions at the June 2, 2026 annual meeting.
Key Terms
nasdaq listing rule 5635(c)(4), restricted share units, rsus, amended and restated 2025 inducement equity incentive plan, +2 more
6 terms
nasdaq listing rule 5635(c)(4)regulatory
"were granted as inducements ... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
restricted share unitsfinancial
"an aggregate of 25,600 share options and 15,000 restricted share units (RSUs)."
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
rsusfinancial
"15,000 restricted share units (RSUs). All of the foregoing share options"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
amended and restated 2025 inducement equity incentive planregulatory
"subject to the terms ... and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan."
An amended and restated 2025 inducement equity incentive plan is an updated written program that grants stock or stock-like awards to new employees as a hiring incentive, with prior rules folded into a single revised document. It matters to investors because it changes how many shares can be issued and how new hires are paid, affecting potential dilution and the alignment of employees’ incentives with shareholder interests—like giving a key hire a piece of the business as a signing bonus.
kv7 potassium channel openermedical
"azetukalner, is a novel, potent, selective KV7 potassium channel opener in Phase 3"
A Kv7 potassium channel opener is a drug that helps certain cellular ‘gates’ called Kv7 channels stay open so potassium can flow out of cells, calming electrical activity in nerves and muscle. For investors, these compounds matter because they can form the basis of treatments for conditions driven by excessive electrical firing—like some seizures, pain, or heart rhythm disorders—so successful candidates can create new medical markets or reduce risks in drug pipelines.
nav1.7medical
"including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain."
NAV1.7 is a specific protein in nerve cells that helps transmit pain signals to the brain; think of it as a gatekeeper that opens and closes to let electrical messages through. Investors watch drugs that block or modify NAV1.7 because successful therapies could relieve chronic pain without opioids, creating large market opportunities, while clinical setbacks or safety issues can sharply affect a company's valuation.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
VANCOUVER, British Columbia and BOSTON, MA, May 01, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 25,600 share options and 15,000 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of April 30, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of $56.04 per common share, which is equal to the closing price per share of Xenon’s common shares on the grant date of April 30, 2026. The share option grants vest over four years, with 25% vesting on the one-year anniversary of the respective employee’s start date and 1/36th of the remaining options vesting monthly thereafter on the last day of each month, subject to such option recipient’s continued service relationship with the Company. Each option has a 10-year term and is subject to the terms and conditions of the share option agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan. The RSUs will vest as to 25% of the underlying shares on each of the first four anniversaries of the respective employee’s start date, subject to such employee’s continued service relationship with the Company. Each RSU grant is subject to the terms and conditions of the restricted share unit award agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan.
About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
For Media: Colleen Alabiso Senior Vice President, Corporate Affairs media@xenon-pharma.com
FAQ
What equity inducement did Xenon (XENE) grant on April 30, 2026?
Xenon granted an aggregate of 25,600 share options and 15,000 RSUs to seven new non-officer employees. According to the company, these grants were approved by the Compensation Committee and issued under Nasdaq Listing Rule 5635(c)(4) as inducements for hiring.
What are the vesting terms and exercise price for Xenon (XENE) share options?
The options vest over four years with 25% after one year and monthly vesting thereafter; each option expires in 10 years. According to the company, the exercise price is $56.04, equal to the April 30, 2026 closing share price.
How do the RSUs granted by Xenon (XENE) vest for new employees?
Each RSU grant vests 25% on each of the first four anniversaries of the employee’s start date. According to the company, RSU vesting is subject to continued service and the terms of the Amended and Restated 2025 Inducement Equity Incentive Plan.
Are Xenon’s April 30, 2026 inducement grants subject to any plan or agreements?
Yes. The options and RSUs are subject to the respective award agreements and the company’s Amended and Restated 2025 Inducement Equity Incentive Plan. According to the company, exercise, vesting, and other terms follow those governing documents.
Will the Xenon (XENE) inducement grants dilute existing shareholders materially?
The company disclosed aggregate grants of 40,600 equity awards but did not quantify total outstanding shares or dilution percentage. According to the company, the grants were issued as standard inducements; investors should compare awards to total shares outstanding to assess dilution.
